Research summary
Research HubIGF-1 LR3
Clinical — 10 studies
IGF-1 LR3 is a modified insulin-like growth factor studied for its extended half-life and receptor binding properties.
Being studied for
- IGF-1 signaling research
- Cell growth and proliferation pathways
Published Research
Evidence profile
Controlled human evidence
10 cited publications · 1 primary trial
Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.
Supporting evidence
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL et al. · The Journal of clinical endocrinology and metabolism · 2006
The study reportedSubcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg. There was evidence of a cumulative effect after multiple doses.
Place of cabergoline in acromegaly: a meta-analysis
Sandret L et al. · The Journal of clinical endocrinology and metabolism · 2011
The study reportedThis meta-analysis suggests that cabergoline single-agent therapy normalizes IGF-I levels in one third of patients with acromegaly. When a somatostatin analog fails to control acromegaly, cabergoline adjunction normalizes IGF-I in about 50% of cases. This effect may occur even in patients with normoprolactinemia.
Additional indexed literature (8)
- Clinical · Mechanistic studyPasireotide as first line medical therapy for selected patients with acromegaly
Olarescu NC et al. · Pituitary · 2025 · PMID 40216609
- Preclinical · Mechanistic studyIntranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice
Engel MG et al. · Journal of Alzheimer's disease : JAD · 2025 · PMID 39610283
- Preclinical · Mechanistic studyRecombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris
Lu Z et al. · Applied microbiology and biotechnology · 2023 · PMID 37261455
- Preclinical · Mechanistic studySheep recombinant IGF-1 promotes organ-specific growth in fetal sheep
Stremming J et al. · Frontiers in physiology · 2022 · PMID 36091374
- Preclinical · Mechanistic studyFood restriction reduces cortical bone mass and serum insulin-like growth factor-1 levels and promotes uterine atrophy in mice
Ito E et al. · Biochemical and biophysical research communications · 2021 · PMID 33288195
- Preclinical · Mechanistic studyInsulin-like growth factor 1 receptor activation promotes mammary gland tumor development by increasing glycolysis and promoting biomass production
Ter Braak B et al. · Breast cancer research : BCR · 2017 · PMID 28173837
- Preclinical · Mechanistic studyDown-regulation of cyclin G2 by insulin, IGF-I (insulin-like growth factor 1) and X10 (AspB10 insulin): role in mitogenesis
Svendsen AM et al. · The Biochemical journal · 2014 · PMID 24059861
- Preclinical · Pharmacokinetic studyTreatment with insulin analog X10 and IGF-1 increases growth of colon cancer allografts
Hvid H et al. · PloS one · 2013 · PMID 24260289
Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Cobalt Peptides material. Citations verified against PubMed on 2026-08-09.
Notice
All information on this page is provided strictly for laboratory research and educational purposes only.